XR-17™ encapsulates individual APIs in a layer of micelles, making the API and micelle formulation water soluble and therefore usable in water based intravenous injections.

Oasmia’s toxicological and clinical studies suggest XR-17’s beneficial properties, which are intended to achieve:

  • Improved delivery of intravenously administered drugs, intended to avoid mandatory use of corticosteroid before intravenous (i.v.) administration
  • Shorter i.v. infusion times than with some solvent based versions of the drugs, making treatment more convenient for patients and healthcare providers
  • Favorable API to solvent ratio, intended to keep solvent portion of the drug low while maximizing the API delivery
  • Free of alcohol and animal and human proteins